Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: TNF inhibitors

Pregnancy Outcomes in Patients Treated with TNF Inhibitors

Michele B. Kaufman, PharmD, BCGP  |  December 18, 2023

A study found the continuation of tumor necrosis factor inhibitor (TNFi) treatment in patients with chronic rheumatic inflammatory diseases after pregnancy diagnosis was not associated with worse outcomes than those who discontinued treatment with TNFi’s.

Filed under:ACR ConvergenceBiologics/DMARDsConditionsDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2023pregnancypregnant womentumor necrosis factor inhibitor (TNFi)

JAK Inhibitors vs. TNF Inhibitors: Understanding Infection Risks

Michele B. Kaufman, PharmD, BCGP  |  April 27, 2023

Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2022InfectionJAK inhibitorsJanus Kinase InhibitorsRheumatoid Arthritis (RA)TNF inhibitorstumor necrosis factor (TNF) inhibitors

TNF Inhibitors Associated with Neurological Adverse Events

Michele B. Kaufman, PharmD, BCGP  |  November 7, 2022

A study examined the association between TNF inhibitors and neurological demyelinating adverse events in patients with rheumatoid arthritis and spondyloarthritis using cohort data from five Nordic countries. Researchers showed that patients with SpA were more likely to experience adverse events than patients with RA.

Filed under:ConditionsDrug Updates Tagged with:adverse eventsbrainEULARneurological demyelinating adverse eventsTNF inhibitorstumor necrosis factor (TNF) inhibitors

TNF Inhibitors & Pregnancy: How Well Does the Treatment Guidance Work?

Michele B. Kaufman, PharmD, BCGP  |  October 21, 2021

Ghalandari et al. sought to validate the guidance outlined by EULAR for the use of anti-rheumatic drugs during pregnancy, finding that following its guidance for tumor necrosis factor inhibitors led to no or low concentrations of these agents in cord blood.

Filed under:Drug UpdatesEULAR/OtherMeeting Reports Tagged with:EULARpregnancypregnant womenTNF inhibitorsTNFiWomen

Live Varicella Zoster Vaccine Safe, Effective with TNF Inhibitors

Lisa Rapaport  |  October 6, 2021

(Reuters Health)—Adults 50 years and older who take tumor necrosis factor inhibitors (TNFi’s) for a range of inflammatory disorders can receive effective protection from shingles with a live varicella zoster vaccine, a clinical trial suggests.1 Researchers randomized 617 participants receiving TNFi’s in a 1:1 ratio to receive either the Zostavax live varicella zoster vaccine or…

Filed under:Biologics/DMARDsDrug Updates Tagged with:live vaccinevaccinevaricella zoster vaccinevaricella zoster virus

Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments

Larry Beresford  |  October 7, 2020

An observational study found treatment with tofacitinib resulted in only a slightly higher rate of venous thromboembolism than tumor necrosis factor inhibitors in patients with rheumatoid arthritis.

Filed under:Drug Updates Tagged with:JAK inhibitorsjakinibRheumatoid Arthritis (RA)TNF inhibitorsTofacitinib

RA Patients May Be Less Likely to Discontinue Etanercept Than Other TNF Inhibitors

Lara C. Pullen, PhD  |  January 8, 2020

In a systematic literature review, researchers found that rheumatoid arthritis patients taking etanercept were less likely to discontinue their treatment than patients using any of five other tumor necrosis factor inhibitors…

Filed under:ConditionsRheumatoid Arthritis Tagged with:etanerceptRheumatoid Arthritis (RA)TNF inhibitors

Do Patients with Ankylosing Spondylitis in Remission Still Need TNF Inhibitors?

Lara C. Pullen, PhD  |  October 24, 2019

Patients with axial spondyloarthritis have a chronic, immune-mediated inflammatory disease that tends to localize to the sacroiliac joints and spine. Ankylosing spondylitis is, perhaps, the most representative of this group of diseases. Rheumatologists treat patients with axial spondyloarthritis with biologics, such as tumor necrosis factor inhibitors (TNFi’s), which can improve quality of life, activity and…

Filed under:Axial SpondyloarthritisConditionsResearch Rheum Tagged with:Ankylosing SpondylitisRemissionTNF inhibitors

For Psoriasis, Ustekinumab & TNF Inhibitors Show Similar Cardiac Safety

David Douglas  |  April 9, 2019

NEW YORK (Reuters Health)—In patients with psoriasis and psoriatic arthritis, the incidence of atrial fibrillation and major adverse cardiovascular events does not differ between treatment with ustekinumab and TNF inhibitors, according to a large observational study. “Given a high cardiovascular risk among patients with psoriasis and psoriatic arthritis,” Seoyoung C. Kim, MD, ScD, MSCE, told…

Filed under:Conditions Tagged with:cardiovascularcardiovascular eventPsoriasisPsoriatic ArthritisSafetyTNF inhibitorustekinumab

RA Effectiveness Differs Among Non-TNF Inhibitors

Will Boggs, MD  |  February 5, 2019

NEW YORK (Reuters Health)—Rheumatoid arthritis (RA) outcomes are better with some non-TNF inhibitors than with others, according to French registry data. “Previously, indirect comparisons (meta-analyses) did not show any difference between biologics in terms of effectiveness,” Dr. Jacques-Eric Gottenberg from Strasbourg University Hospital, France, tells Reuters Health by email. “Our direct comparison using observational data…

Filed under:ConditionsRheumatoid Arthritis Tagged with:abataceptnon-TNF inhibitorsRheumatoid Arthritis (RA)rituximabtocilizumab

  • 1
  • 2
  • 3
  • …
  • 42
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences